(Q46621429)

23 December 2017

meta-analysis

0 references

title

A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma (English)

1 reference

23 December 2017

positron emission tomography

0 references

1 reference

1 reference

1

Carmen R Isasi

1 reference

23 December 2017

author name string

Ping Lu

series ordinal

2

1 reference

23 December 2017

M Donald Blaufox

series ordinal

3

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

23 December 2017

published in

Cancer

1 reference

23 December 2017

volume

104

1 reference

23 December 2017

issue

5

1 reference

23 December 2017

page(s)

1066-1074

1 reference

23 December 2017

18F-fluorodeoxyglucose-positron emission tomography in the staging of malignant lymphoma compared with CT and 67Ga scan

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

Advantages of positron emission tomography (PET) with respect to computed tomography in the follow-up of lymphoma patients with abdominal presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

Why sources of heterogeneity in meta-analysis should be investigated

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

Positron emission tomography scanning: current and future applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

FDG-PET/CT in re-staging of patients with lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Conventional imaging and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography for predicting the clinical outcome of previously treated non-hodgkin's lymphoma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

2-deoxy-2-[F-18]fluoro-D-glucose imaging with positron emission tomography for initial staging of Hodgkin's disease and lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

[(18)F]FDG in childhood lymphoma: clinical utility and impact on management

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

F-18 FDG versus Ga-67 for detecting splenic involvement in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Imaging of malignant lymphomas with F-18 FDG coincidence detection positron emission tomography

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Camera-based FDG PET and 67Ga SPECT in evaluation of lymphoma: comparative study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Utility of FDG-PET scanning in lymphoma by WHO classification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Clinical relevance of positron emission tomography (PET) in treatment control and relapse of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Accuracy of Whole‐Body 18F‐FDP‐PET for Restaging Malignant Lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

[18F] FDG PET in gastric non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Advances in the treatment of Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Meta-analytic methods for diagnostic test accuracy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Exploring sources of heterogeneity in systematic reviews of diagnostic tests

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Extranodal malignant lymphoma: detection with FDG PET versus CT

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Positron emission tomography for the staging of Hodgkin's lymphoma--increasing the body of evidence in favor of the method

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21253

7 January 2021

Identifiers

DOI

10.1002/CNCR.21253

1 reference

23 December 2017

release_r3r4vgabzvh6nkcbq5hxbogqqy

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/r3r4vgabzvh6nkcbq5hxbogqqy

24 November 2022

mapped directly with Wikidata item

1 reference

23 December 2017